{
  "id": "5895dfc97d9090f353000010",
  "type": "list",
  "question": "List active ingredients of the Stribild polypill.",
  "ideal_answer": "Active ingredients of Stribild are elvitegravir, cobicistat, emtricitabine and tenofovir. It is used for treatment of HIV infection.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24338165",
    "http://www.ncbi.nlm.nih.gov/pubmed/25553805",
    "http://www.ncbi.nlm.nih.gov/pubmed/27225853",
    "http://www.ncbi.nlm.nih.gov/pubmed/26286337",
    "http://www.ncbi.nlm.nih.gov/pubmed/23136357",
    "http://www.ncbi.nlm.nih.gov/pubmed/26045359",
    "http://www.ncbi.nlm.nih.gov/pubmed/26679246"
  ],
  "snippets": [
    {
      "text": "PURPOSE: The purpose of this study is to assess postmarketing safety and tolerability of Stribild (elvitegravir [EVG]/cobicistat [COBI]/tenofovir disoproxil fumarate [TDF]/emtricitabine [FTC]).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27225853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir (EVG/COBI/FTC/TDF or Stribild\u2122) is the latest antiretroviral tablet approved in the EU. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25553805",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(\u00ae)) is a guideline-recommended regimen for HIV treatment-na\u00efve patients and a switch option for virologically suppressed patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26045359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(\u00ae)) is a recommended integrase inhibitor-based regimen in treatment guidelines from the US Department of Health and Human Services and the British HIV Association. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26286337",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild\u00ae): a review of its use in the management of HIV-1 infection in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24338165",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A new single-tablet, fixed-dose formulation consisting of elvitegravir, an HIV-1 integrase strand transfer inhibitor (INSTI); cobicistat, a pharmacokinetic enhancer; emtricitabine, a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil fumarate (tenofovir DF), a nucleotide reverse transcriptase inhibitor (elvitegravir/cobicistat/emtricitabine/tenofovir DF 150 mg/150 mg/200 mg/300 mg; Stribild\u00ae) is available in some countries for the once-daily treatment of HIV-1 infection in antiretroviral therapy-na\u00efve adults. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24338165",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To review the clinical trials, pharmacologic characteristics, safety, and efficacy of the elvitegravir/cobicistat/emtricitabine/tenofovir single tablet formulation (Stribild).Literature searches were performed in MEDLINE (1948-September 2012) and PubMed (1966-September 2012) using the search terms GS-9137, elvitegravir, GS 9350, cobicistat, quad pill, Stribild, and integrase inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23136357",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation.Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day wash-out period, and then received elvitegravir/cobicistat as part of Stribild(\u00ae) (245 mg of tenofovir, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679246",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "elvitegravir, cobicistat, emtricitabine, tenofovir"
}